Skip to Main Content

Paper Details

OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis.
Leukemia
34
2020
Author NameAffiliation
Richard B LockChildren's Cancer Institute
Michelle J HendersonChildren's Cancer Institute
Michelle HaberChildren's Cancer Institute
  • 1 - 3

Datasets

Release 1.2